Frederick J. Ruegsegger
Corporate Officer/Principal bei Four Oaks Partners LLC
Profil
Frederick J.
Ruegsegger currently works at Four Oaks Partners LLC, as Managing Director from 2012.
Mr. Ruegsegger also formerly worked at EyeSys Technologies, Inc., as President & Chief Executive Officer from 1993 to 1996, Vitaphore Corp., as President & Chief Executive Officer from 1991 to 1993, Novacea, Inc., as Director from 2008 to 2009, Transcept Pharma, Inc., as Director from 2009 to 2011, Sotera Health LLC, as Chief Financial Officer, Axys Pharmaceuticals, Inc., as CFO, SVP-Finance & Corporate Development from 1996 to 1999, Ion Beam Applications SA, as Chief Financial & Staffing Officer in 2004, and Neoforma.com, Inc., as Chief Financial Officer from 1999 to 2000.
Mr. Ruegsegger received his undergraduate degree from the University of Illinois and graduate degree from Kellogg School of Management.
Aktive Positionen von Frederick J. Ruegsegger
| Unternehmen | Position | Beginn |
|---|---|---|
| Four Oaks Partners LLC | Corporate Officer/Principal | 01.04.2012 |
Ehemalige bekannte Positionen von Frederick J. Ruegsegger
| Unternehmen | Position | Ende |
|---|---|---|
Novacea, Inc.
 Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Direktor/Vorstandsmitglied | 03.02.2009 |
| ION BEAM APPLICATIONS, SA | Finanzdirektor/CFO | 01.06.2004 |
| Neoforma.com, Inc. | Finanzdirektor/CFO | 01.10.2000 |
Axys Pharmaceuticals, Inc.
 Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | Finanzdirektor/CFO | 01.07.1999 |
EyeSys Technologies, Inc.
 EyeSys Technologies, Inc. Medical SpecialtiesHealth Technology EyeSys Technologies, Inc. develops corneal topography systems. The company is based in Houston, TX. EyeSys Technologies was acquired by Premier Laser Systems, Inc. on October 01, 1997 for $12 million. | Präsident | 01.12.1996 |
Ausbildung von Frederick J. Ruegsegger
| University of Illinois | Undergraduate Degree |
| Kellogg School of Management | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ION BEAM APPLICATIONS, SA | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Sotera Health LLC
 Sotera Health LLC Medical/Nursing ServicesHealth Services Sotera Health LLC offers sterilization services. It offers medical device sterilization, pharmaceutical sterilization, food and commercial products safety, packaging materials, laboratory testing, and consulting services. The company was founded in 2017 and is headquartered in Broadview Heights, OH. | Health Services |
Axys Pharmaceuticals, Inc.
Axys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Axys Pharmaceuticals, Inc. engages in the development of integrated drugs. The company is headquartered in South San Francisco, CA. | Health Technology |
| Neoforma.com, Inc. | Health Technology |
EyeSys Technologies, Inc.
EyeSys Technologies, Inc. Medical SpecialtiesHealth Technology EyeSys Technologies, Inc. develops corneal topography systems. The company is based in Houston, TX. EyeSys Technologies was acquired by Premier Laser Systems, Inc. on October 01, 1997 for $12 million. | Health Technology |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
| Vitaphore Corp. | |
Transcept Pharma, Inc.
 Transcept Pharma, Inc. Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Its product pipeline is TO-2070, a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine as the active drug. The company was founded on January 30, 2009 and is headquartered in Point Richmond, CA. | Health Technology |
| Four Oaks Partners LLC |
